STAAR Surgical Cash Flow from Investing Activities 2010-2023 | STAA
STAAR Surgical cash flow from investing activities from 2010 to 2023. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
| STAAR Surgical Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2023 | $74 |
| 2022 | $-156 |
| 2021 | $-14 |
| 2020 | $-8 |
| 2019 | $-10 |
| 2018 | $-2 |
| 2017 | $-1 |
| 2016 | $-3 |
| 2015 | $-2 |
| 2014 | $-4 |
| 2013 | $-3 |
| 2012 | $-2 |
| 2011 | $-1 |
| 2010 | $19 |
| 2009 | $-8 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $2.141B | $0.322B |
| Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $72.091B | 20.23 |
| Becton Dickinson (BDX) | United States | $68.480B | 19.37 |
| West Pharmaceutical Services (WST) | United States | $26.090B | 46.76 |
| Cardinal Health (CAH) | United States | $23.879B | 13.65 |
| Align Technology (ALGN) | United States | $20.532B | 39.64 |
| Cooper (COO) | United States | $18.451B | 27.92 |
| Labcorp (LH) | United States | $17.734B | 15.27 |
| Henry Schein (HSIC) | United States | $9.364B | 16.66 |
| DENTSPLY SIRONA (XRAY) | United States | $5.851B | 15.15 |
| Merit Medical Systems (MMSI) | United States | $4.697B | 25.74 |
| Patterson (PDCO) | United States | $2.290B | 10.97 |
| CONMED (CNMD) | United States | $2.242B | 20.33 |
| Atrion (ATRI) | United States | $0.774B | 41.33 |
| Lifevantage (LFVN) | United States | $0.086B | 11.10 |
| Pro-Dex (PDEX) | United States | $0.065B | 32.60 |
| Biolase (BIOL) | United States | $0.006B | 0.00 |